论文部分内容阅读
Objective: To observe the effects of cytokine-induced killer (CIK) cells on the treatment of renal cell carcinoma. Methods: Twenty-eight postoperative cases with stage I or stage II renal cell carcinoma were admitted in our hospital from January 2002 to June 2006, all cases were pathologically confirmed, and were divided into group A (18 cases) and group B (10 cases). Group A was administrated 3–12 periods of CIK cells treatment combined with 5–7 cycles of IL-2 and INFα-2b, together with 4 cycles of chemotherapy (5-Fu + CF). Group B was given 4 cycles of chemotherapy (5-Fu + CF) and 5–7 cycles of IL-2 and INFα-2b. Results: Three cases in group A had metastatic masses in two lungs within 1 year and died within 2 years postoperatively. The other 15 cases are still alive and in good health. Six cases in group B had metastatic masses in two lungs or/and in abdominal cavity within 1 year, and 4 of them died within 2 years. All the 6 cases died within 3 years. The other 4 cases are still alive and in good health. Conclusion: CIK cells are safe and effective for the treatment of stage I or stage II renal cell carcinoma, which should be further widely used.
Methods: Twenty-eight postoperative cases with stage I or stage II renal cell carcinoma were admitted in our hospital from January 2002 to June 2006 , all cases were pathologically confirmed, and were divided into group A (18 cases) and group B (10 cases). Group A was administrated 3-12 periods of CIK cells treatment combined with 5-7 cycles of IL-2 and INFα- 2b, together with 4 cycles of chemotherapy (5-Fu + CF). Group B was given 4 cycles of chemotherapy (5-Fu + CF) and 5-7 cycles of IL- group A had metastatic masses in two lungs within 1 year and died within 2 years postoperatively. The other 15 cases are still alive and in good health. Six cases in group B had metastatic masses in two lungs or / and in abdominal cavities within 1 year , and 4 of them died within 2 years. All the 6 cases died within 3 years. The other 4 cases are s till alive and in good health. Conclusion: CIK cells are safe and effective for the treatment of stage I or stage II renal cell carcinoma, which should be further widely used.